Irish rare disease research center FutureNeuro is partnering with software vendor Congenica to bring sequencing to the point of care for genetic epilepsies.
Following some major integration issues and other data challenges, Stanford is preparing to expand genomic medicine beyond rare diseases and cancer.
Amgen will use BC Platforms' tools and services to study data in multiple indications, including cardiovascular and bone diseases, hematological malignancies, and other cancers.
Organizers will not only collect genetic data on participants, but report back genetic risks via the country's national health information system.
The project, dubbed FinnGen, was announced this week and is slated to run through mid-2023.
The Office of the National Coordinator for Health IT sees long-term potential in APIs for secure transfer of clinical and genomic data, but it's not quite there yet on the genomic side.
The head of the data center for the Precision Medicine Initiative's All of Us program discusses plans to manage records on 1 million people from dozens of sites.
The companies believe the database can facilitate outcomes research, improve variant interpretations, inform drug development efforts.
Brigham & Women's Ravi Parikh coauthored a recent NEJM commentary calling for a Precision Delivery Initiative to supplement the Precision Medicine Initiative.
An international team of researchers has mapped new associations between HLA mutations and specific diseases, and made their data freely accessible.
US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.
The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.
Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.
In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.